Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Aberrant Methylation of LINE-1 Transposable Elements: A Search for Cancer Biomarkers

AA. Ponomaryova, EY. Rykova, PA. Gervas, NV. Cherdyntseva, IZ. Mamedov, TL. Azhikina

. 2020 ; 9 (9) : . [pub] 20200902

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc21012164

Cancer remains one of the main causes of human mortality despite significant progress in its diagnostics and therapy achieved in the past decade. Massive hypomethylation of retrotransposons, in particular LINE-1, is considered a hallmark of most malignant transformations as it results in the reactivation of retroelements and subsequent genomic instability. Accumulating data on LINE-1 aberrant methylation in different tumor types indicates its significant role in cancer initiation and progression. However, direct evidence that LINE-1 activation can be used as a cancer biomarker is still limited. The objective of this review was to critically evaluate the published results regarding the diagnostic/prognostic potential of the LINE-1 methylation status in cancer. Our analysis indicates that LINE-1 hypomethylation is a promising candidate biomarker of cancer development, which, however, needs validation in both clinical and laboratory studies to confirm its applicability to different cancer types and/or stages. As LINE-1 is present in multiple cell-free copies in blood, it has advantages over single-copy genes regarding perspectives of using its methylation status as an epigenetic cancer biomarker for cell-free DNA liquid biopsy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21012164
003      
CZ-PrNML
005      
20210714095238.0
007      
ta
008      
210420s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cells9092017 $2 doi
035    __
$a (PubMed)32887319
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Ponomaryova, Anastasia A $u Cancer Research Institute, Tomsk National Research Medical Center, 634009 Tomsk, Russia
245    10
$a Aberrant Methylation of LINE-1 Transposable Elements: A Search for Cancer Biomarkers / $c AA. Ponomaryova, EY. Rykova, PA. Gervas, NV. Cherdyntseva, IZ. Mamedov, TL. Azhikina
520    9_
$a Cancer remains one of the main causes of human mortality despite significant progress in its diagnostics and therapy achieved in the past decade. Massive hypomethylation of retrotransposons, in particular LINE-1, is considered a hallmark of most malignant transformations as it results in the reactivation of retroelements and subsequent genomic instability. Accumulating data on LINE-1 aberrant methylation in different tumor types indicates its significant role in cancer initiation and progression. However, direct evidence that LINE-1 activation can be used as a cancer biomarker is still limited. The objective of this review was to critically evaluate the published results regarding the diagnostic/prognostic potential of the LINE-1 methylation status in cancer. Our analysis indicates that LINE-1 hypomethylation is a promising candidate biomarker of cancer development, which, however, needs validation in both clinical and laboratory studies to confirm its applicability to different cancer types and/or stages. As LINE-1 is present in multiple cell-free copies in blood, it has advantages over single-copy genes regarding perspectives of using its methylation status as an epigenetic cancer biomarker for cell-free DNA liquid biopsy.
650    _2
$a protinádorové látky $x terapeutické užití $7 D000970
650    _2
$a nádorové biomarkery $x krev $x genetika $7 D014408
650    _2
$a volné cirkulující nukleové kyseliny $x krev $x genetika $7 D000073888
650    _2
$a metylace DNA $7 D019175
650    12
$a transpozibilní elementy DNA $7 D004251
650    _2
$a progrese nemoci $7 D018450
650    _2
$a epigeneze genetická $7 D044127
650    12
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a nestabilita genomu $7 D042822
650    _2
$a lidé $7 D006801
650    _2
$a tekutá biopsie $7 D000073890
650    12
$a dlouhé rozptýlené jaderné elementy $7 D020084
650    _2
$a nádory $x diagnóza $x farmakoterapie $x genetika $x mortalita $7 D009369
650    _2
$a prognóza $7 D011379
650    _2
$a signální transdukce $7 D015398
650    _2
$a analýza přežití $7 D016019
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Rykova, Elena Y $u Institute of Chemical Biology and Fundamental Medicine, Siberian Division of the Russian Academy of Sciences, 630090 Novosibirsk, Russia ; Department of Engineering Issues in Ecology, Novosibirsk State Technical University, 630073 Novosibirsk, Russia
700    1_
$a Gervas, Polina A $u Cancer Research Institute, Tomsk National Research Medical Center, 634009 Tomsk, Russia
700    1_
$a Cherdyntseva, Nadezhda V $u Cancer Research Institute, Tomsk National Research Medical Center, 634009 Tomsk, Russia
700    1_
$a Mamedov, Ilgar Z $u Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia ; Central European Institute of Technology, Masaryk University, 625 00 Brno, Czech Republic ; Laboratory of Molecular Pathophysiology, V.I. Kulakov National Medical Research Center for Obsterics, 117997 Moscow, Russia
700    1_
$a Azhikina, Tatyana L $u Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia
773    0_
$w MED00194911 $t Cells $x 2073-4409 $g Roč. 9, č. 9 (2020)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32887319 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210714095237 $b ABA008
999    __
$a ok $b bmc $g 1650523 $s 1132543
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 9 $c 9 $e 20200902 $i 2073-4409 $m Cells $n Cells $x MED00194911
LZP    __
$a Pubmed-20210420

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace